Therapy Areas: Hereditary Disorders
12 March 2019 - - The Therapeutic Goods Administration of Australia has granted registration to Symdeko (tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis aged 12 ye...
8 March 2019 - - Treatment with the triple combination of the next-generation corrector VX-445, tezacaftor and ivacaftor resulted in statistically significant improvements in lung function (percent pr...
20 February 2019 - - US-based biotechnology company Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) has received the results of a Phase 3 study conducted in Europe and Australia of tezacaftor in combi...
13 February 2019 - - US-based healthcare technology company ZappRx will work with Israel-based Teva Respiratory, LLC, in support of their specialty respiratory medication, the company said.

30 January 2019 - - US-based specialty pharmaceutical company Aradigm Corp. (OTCQB: ARDM) submitted responses to the European Medicines Agency Day 120 questions on 23 January 2019, the company said.
30 January 2019 - Health Canada has granted Market Authorisation to United States-based Vertex Pharmaceuticals' KALYDECO (ivacaftor) to include use in children with cystic fibrosis (CF) aged 12 t...
Related Headlines